BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19642417)

  • 1. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.
    Clark RC; Lee SY; Searcey M; Boger DL
    Nat Prod Rep; 2009 Apr; 26(4):465-77. PubMed ID: 19642417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.
    Duncan SJ; Grüschow S; Williams DH; McNicholas C; Purewal R; Hajek M; Gerlitz M; Martin S; Wrigley SK; Moore M
    J Am Chem Soc; 2001 Jan; 123(4):554-60. PubMed ID: 11456567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin.
    Cominetti MMD; Goffin SA; Raffel E; Turner KD; Ramoutar JC; O'Connell MA; Howell LA; Searcey M
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4878-4880. PubMed ID: 26115576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid-phase synthesis of the cyclic peptide portion of chlorofusin, an inhibitor of p53-MDM2 interactions.
    Malkinson JP; Zloh M; Kadom M; Errington R; Smith PJ; Searcey M
    Org Lett; 2003 Dec; 5(26):5051-4. PubMed ID: 14682762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
    Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
    Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
    Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
    Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
    Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
    Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structures.
    Clark RC; Lee SY; Boger DL
    J Am Chem Soc; 2008 Sep; 130(37):12355-69. PubMed ID: 18712872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
    Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
    Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
    Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
    Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
    Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
    Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
    Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.